SE9702401D0 - Pharmaceutical use - Google Patents

Pharmaceutical use

Info

Publication number
SE9702401D0
SE9702401D0 SE9702401A SE9702401A SE9702401D0 SE 9702401 D0 SE9702401 D0 SE 9702401D0 SE 9702401 A SE9702401 A SE 9702401A SE 9702401 A SE9702401 A SE 9702401A SE 9702401 D0 SE9702401 D0 SE 9702401D0
Authority
SE
Sweden
Prior art keywords
pharmaceutical use
parathyroid hormone
osteoporosis
medicament
year
Prior art date
Application number
SE9702401A
Other languages
English (en)
Swedish (sv)
Inventor
Sverker Ljunghall
Sven Sjoegren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9702401A priority Critical patent/SE9702401D0/xx
Publication of SE9702401D0 publication Critical patent/SE9702401D0/xx
Priority to DE69841279T priority patent/DE69841279D1/de
Priority to CA2698626A priority patent/CA2698626C/en
Priority to EP98929965A priority patent/EP1001802B1/en
Priority to PCT/SE1998/001095 priority patent/WO1998057656A1/en
Priority to JP50425999A priority patent/JP4989811B2/ja
Priority to PT98929965T priority patent/PT1001802E/pt
Priority to EP04017622A priority patent/EP1473040B1/en
Priority to DE69826132T priority patent/DE69826132T2/de
Priority to ES04017622T priority patent/ES2335404T3/es
Priority to AT04017622T priority patent/ATE447410T1/de
Priority to PT04017622T priority patent/PT1473040E/pt
Priority to AT98929965T priority patent/ATE275419T1/de
Priority to AU79458/98A priority patent/AU753477B2/en
Priority to DK98929965T priority patent/DK1001802T3/da
Priority to US09/125,247 priority patent/US6284730B1/en
Priority to DK04017622.4T priority patent/DK1473040T3/da
Priority to CA2294101A priority patent/CA2294101C/en
Priority to ES98929965T priority patent/ES2229511T3/es
Priority to ZA984947A priority patent/ZA984947B/xx
Priority to HK00107524A priority patent/HK1029738A1/xx
Priority to US09/942,661 priority patent/US20020002135A1/en
Priority to US10/389,797 priority patent/US7018982B2/en
Priority to HK05103473.5A priority patent/HK1070816A1/xx
Priority to US11/305,339 priority patent/US7507715B2/en
Priority to US12/351,558 priority patent/US7749543B2/en
Priority to JP2010000066A priority patent/JP5525825B2/ja
Priority to CY20101100091T priority patent/CY1110287T1/el
Priority to US12/822,089 priority patent/US8153588B2/en
Priority to US13/405,093 priority patent/US8765674B2/en
Priority to JP2013206919A priority patent/JP2014015479A/ja
Priority to US14/285,437 priority patent/US20140256632A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE9702401A 1997-06-19 1997-06-19 Pharmaceutical use SE9702401D0 (sv)

Priority Applications (32)

Application Number Priority Date Filing Date Title
SE9702401A SE9702401D0 (sv) 1997-06-19 1997-06-19 Pharmaceutical use
CA2698626A CA2698626C (en) 1997-06-19 1998-06-08 A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
DK98929965T DK1001802T3 (da) 1997-06-19 1998-06-08 Farmaceutisk kombinationspræparat af parathyroidhormon og en knogleresorptionsinhibitor
CA2294101A CA2294101C (en) 1997-06-19 1998-06-08 A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
US09/125,247 US6284730B1 (en) 1997-06-19 1998-06-08 Methods useful in the treatment of bone resorption diseases
PCT/SE1998/001095 WO1998057656A1 (en) 1997-06-19 1998-06-08 A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
JP50425999A JP4989811B2 (ja) 1997-06-19 1998-06-08 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤
PT98929965T PT1001802E (pt) 1997-06-19 1998-06-08 Preparacao farmaceutica combinada compreendendo a hormona da paratiroide e um inibidor de reabsorcao ossea
EP04017622A EP1473040B1 (en) 1997-06-19 1998-06-08 Use of human parathyroid hormone
DE69826132T DE69826132T2 (de) 1997-06-19 1998-06-08 Pharmazeutisches kombinationspräparat aus parathormon und einem inhibitor der knochenresorption
ES04017622T ES2335404T3 (es) 1997-06-19 1998-06-08 Utilizacion de la hormona paratiroidea humana.
AT04017622T ATE447410T1 (de) 1997-06-19 1998-06-08 Verwendung von humanem parathyroid-hormon
PT04017622T PT1473040E (pt) 1997-06-19 1998-06-08 Utilização de hormona paratiróide humana
AT98929965T ATE275419T1 (de) 1997-06-19 1998-06-08 Pharmazeutisches kombinationspräparat aus parathormon und einem inhibitor der knochenresorption
AU79458/98A AU753477B2 (en) 1997-06-19 1998-06-08 A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
DE69841279T DE69841279D1 (de) 1997-06-19 1998-06-08 Verwendung von humanem Parathyroid-hormon
EP98929965A EP1001802B1 (en) 1997-06-19 1998-06-08 A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
ZA984947A ZA984947B (en) 1997-06-19 1998-06-08 Pharmaceutical use
DK04017622.4T DK1473040T3 (da) 1997-06-19 1998-06-08 Anvendelse af humant parathyroidhormon
ES98929965T ES2229511T3 (es) 1997-06-19 1998-06-08 Preparacion farmaceutica combinada que comprende una hormona paratiroidea y un inhibidor de la resorcion osea.
HK00107524A HK1029738A1 (en) 1997-06-19 2000-11-23 A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor.
US09/942,661 US20020002135A1 (en) 1997-06-19 2001-08-31 Pharmaceutical use
US10/389,797 US7018982B2 (en) 1997-06-19 2003-03-18 Methods useful in the treatment of bone resorption diseases
HK05103473.5A HK1070816A1 (en) 1997-06-19 2005-04-22 Use of human parathyroid hormone
US11/305,339 US7507715B2 (en) 1997-06-19 2005-12-19 Methods useful in the treatment of bone resorption diseases
US12/351,558 US7749543B2 (en) 1997-06-19 2009-01-09 Methods useful in the treatment of bone resorption diseases
JP2010000066A JP5525825B2 (ja) 1997-06-19 2010-01-04 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤
CY20101100091T CY1110287T1 (el) 1997-06-19 2010-01-29 Χρηση της ανθρωπινης παραθυρεοειδους ορμονης
US12/822,089 US8153588B2 (en) 1997-06-19 2010-06-23 Methods useful in the treatment of bone resorption diseases
US13/405,093 US8765674B2 (en) 1997-06-19 2012-02-24 Methods useful in the treatment of bone resorption diseases
JP2013206919A JP2014015479A (ja) 1997-06-19 2013-10-02 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤
US14/285,437 US20140256632A1 (en) 1997-06-19 2014-05-22 Methods useful in the treatment of bone resorption diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702401A SE9702401D0 (sv) 1997-06-19 1997-06-19 Pharmaceutical use

Publications (1)

Publication Number Publication Date
SE9702401D0 true SE9702401D0 (sv) 1997-06-19

Family

ID=20407482

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9702401A SE9702401D0 (sv) 1997-06-19 1997-06-19 Pharmaceutical use

Country Status (15)

Country Link
US (8) US6284730B1 (xx)
EP (2) EP1473040B1 (xx)
JP (3) JP4989811B2 (xx)
AT (2) ATE447410T1 (xx)
AU (1) AU753477B2 (xx)
CA (2) CA2698626C (xx)
CY (1) CY1110287T1 (xx)
DE (2) DE69826132T2 (xx)
DK (2) DK1473040T3 (xx)
ES (2) ES2229511T3 (xx)
HK (2) HK1029738A1 (xx)
PT (2) PT1001802E (xx)
SE (1) SE9702401D0 (xx)
WO (1) WO1998057656A1 (xx)
ZA (1) ZA984947B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
JP4722375B2 (ja) 2000-06-20 2011-07-13 ノバルティス アーゲー ビホスホネートの投与法
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
DE60218842T2 (de) 2001-06-01 2007-12-20 Novartis Ag Orale verabreichung von parathyroidhormon und calcitonin
ATE285756T1 (de) * 2001-06-28 2005-01-15 Microchips Inc Verfahren zum hermetischen versiegeln von mikrochip-reservoir-vorrichtungen
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2004022033A1 (en) * 2002-09-04 2004-03-18 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
PL1656372T3 (pl) 2003-07-30 2013-08-30 Rigel Pharmaceuticals Inc Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
WO2005046798A1 (en) * 2003-11-12 2005-05-26 Nps Allelix Corp. Treatment of bone loss utilizing full length parathyroid hormone
AU2006208131A1 (en) 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
WO2006135915A2 (en) 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
ATE352714T1 (de) * 2005-06-17 2007-02-15 Magneti Marelli Powertrain Spa Brennstoffeinspritzventil
AU2006315132A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2010115932A1 (en) * 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
BR112012003511A2 (pt) * 2009-09-09 2019-09-24 Asahi Kasei Pharma Corp agente para o tratamento ou prevenção de osteoporose, preparação de combinação ou kit de tratamento, e, agente para a inibição ou prevenção de fraturas ósseas
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US10064890B2 (en) 2011-12-13 2018-09-04 Amorphical Ltd. Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders
AU2016226103A1 (en) * 2015-03-03 2017-08-31 Radius Health, Inc. Uses of PTHrP analogue in reducing fracture risk
CN117137872A (zh) 2015-06-04 2023-12-01 艾玛菲克有限公司 用聚磷酸/聚磷酸酯/聚磷酸盐或双膦酸/双膦酸酯/双膦酸盐稳定的无定形碳酸钙
WO2018078616A1 (en) 2016-10-25 2018-05-03 Amorphical Ltd Amorphous calcium carbonate for treating a leukemia

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3768177A (en) * 1972-08-02 1973-10-30 R Thomas Educational device
US3886132A (en) * 1972-12-21 1975-05-27 Us Health Human parathyroid hormone
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4468464A (en) * 1974-11-04 1984-08-28 The Board Of Trustees Of The Leland Stanford Junior University Biologically functional molecular chimeras
US4105602A (en) * 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
US4016314A (en) * 1975-06-26 1977-04-05 Hallco Inc. Embroidered fruit bowl wall hanging and kit for making same
US4264731A (en) * 1977-05-27 1981-04-28 The Regents Of The University Of California DNA Joining method
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4199060A (en) * 1978-07-20 1980-04-22 Howard Hardware Products, Inc. Lock installation kit
US4425437A (en) * 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4383066A (en) 1980-04-15 1983-05-10 Mitsubishi Gas Chemical Company, Inc. Polyphenylene ether resin composition
JPS5825439B2 (ja) 1980-12-30 1983-05-27 株式会社林原生物化学研究所 ヒト副甲状腺ホルモンの製造方法
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4624926A (en) * 1981-01-02 1986-11-25 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
NO163060C (no) 1981-03-13 1990-03-28 Damon Biotech Inc Fremgangsmaate for fremstilling av substanser som dannes av levende celler som produserer interferoner eller antistoffer.
US4385212A (en) 1981-10-05 1983-05-24 Bell Telephone Laboratories Incorporated Expandable communication terminal housing
US4424278A (en) * 1981-11-16 1984-01-03 Research Corporation Cancer detection procedure using an acyl carrier protein
US4532207A (en) * 1982-03-19 1985-07-30 G. D. Searle & Co. Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4595658A (en) * 1982-09-13 1986-06-17 The Rockefeller University Method for facilitating externalization of proteins synthesized in bacteria
WO1984001173A1 (en) 1982-09-15 1984-03-29 Immuno Nuclear Corp Production of mature proteins in transformed yeast
DE3312928A1 (de) 1983-04-11 1984-11-22 Gesellschaft für Biotechnologische Forschung mbH (GBF), 3300 Braunschweig Human-parathormon produzierende hybridvektoren und human-parathormongen
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4588684A (en) * 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
US4637980A (en) 1983-08-09 1987-01-20 Smithkline Beckman Corporation Externalization of products of bacteria
CA1213537A (en) 1984-05-01 1986-11-04 Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee Polypeptide expression method
ATE78515T1 (de) 1984-10-05 1992-08-15 Genentech Inc Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung.
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
HU204563B (en) 1984-12-06 1992-01-28 Synergen Biolog Inc Process for producing recombinant serine-protease inhibitors and dns sequencyes for them
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
IL78342A (en) 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
IE67035B1 (en) 1986-07-08 1996-02-21 Genetics Inst Production and use of non-glycosylated IL-6
US5010010A (en) * 1986-10-22 1991-04-23 Selmer-Sande, A.S. Production of human parathyroid hormone from microorganisms
US5420242A (en) * 1986-10-22 1995-05-30 Kaare M. Gautvik Production of human parathyroid hormone from microorganisms
WO1988003171A1 (en) 1986-10-30 1988-05-05 Synergen Biologicals, Inc. Human pancreatic secretory trypsin inhibitors produced by recombinant dna methods and processes for the production of same
FI77278C (fi) 1986-10-31 1989-02-10 Ahlstroem Oy Foerfarande och anordning foer foerbraenning av sodasvartlut.
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
FR2618914B1 (fr) 1987-07-31 1991-12-06 Alain Souloumiac Perfectionnements apportes aux interrupteurs optomagnetiques
US5059587A (en) 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
EP0318184A1 (en) 1987-11-12 1989-05-31 Schering Corporation Acceleration of bone formation with GM-CSF
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5223407A (en) * 1988-08-31 1993-06-29 Allelix Inc. Excretion of heterologous proteins from e. coli
US5011678A (en) 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
USRE37919E1 (en) * 1989-05-12 2002-12-03 The General Hospital Corporation Recombinant DNA method for production of parathyroid hormone
US5171670A (en) * 1989-05-12 1992-12-15 The General Hospital Corporation Recombinant dna method for production of parathyroid hormone
US5744444A (en) * 1989-10-27 1998-04-28 Haemopep Pharma Gmbh HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
GB9020544D0 (en) 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
JP2557779B2 (ja) * 1990-11-26 1996-11-27 アール． レッカー，ロバート ２成分型骨粗鬆症用薬剤
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
AU3095092A (en) * 1991-12-09 1993-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
BR9206941A (pt) * 1991-12-17 1995-05-02 Procter & Gamble Pharma Métodos para o tratamento da osteoporose usando-se bifosfonatos e hormônio paratireóideo
IT1255723B (it) 1992-10-09 1995-11-13 Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
TW303299B (xx) 1993-07-22 1997-04-21 Lilly Co Eli
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
JP2001503728A (ja) 1994-09-09 2001-03-21 ザ、プロクター、エンド、ギャンブル、カンパニー 骨粗鬆症治療用のエストロゲン及び副甲状腺ホルモン
KR970705400A (ko) * 1994-09-09 1997-10-09 레이셔 야코버스 코넬리스 골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법(methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone)
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
US5550134A (en) 1995-05-10 1996-08-27 Eli Lilly And Company Methods for inhibiting bone loss
US5599822A (en) 1995-06-06 1997-02-04 Eli Lilly And Company Methods for minimizing bone loss
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US5945412A (en) 1996-12-09 1999-08-31 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use

Also Published As

Publication number Publication date
EP1001802A1 (en) 2000-05-24
US20120148684A1 (en) 2012-06-14
CA2294101C (en) 2010-08-03
US20060211613A1 (en) 2006-09-21
US8765674B2 (en) 2014-07-01
ATE447410T1 (de) 2009-11-15
ES2335404T3 (es) 2010-03-26
JP2010100644A (ja) 2010-05-06
US7749543B2 (en) 2010-07-06
US7018982B2 (en) 2006-03-28
EP1001802B1 (en) 2004-09-08
EP1473040B1 (en) 2009-11-04
EP1473040A1 (en) 2004-11-03
US20110071081A1 (en) 2011-03-24
JP5525825B2 (ja) 2014-06-18
AU7945898A (en) 1999-01-04
US20020002135A1 (en) 2002-01-03
US7507715B2 (en) 2009-03-24
DK1473040T3 (da) 2010-03-15
DE69841279D1 (de) 2009-12-17
JP2014015479A (ja) 2014-01-30
PT1001802E (pt) 2005-01-31
DE69826132D1 (de) 2004-10-14
CY1110287T1 (el) 2015-01-14
CA2698626A1 (en) 1998-12-23
ATE275419T1 (de) 2004-09-15
JP4989811B2 (ja) 2012-08-01
DK1001802T3 (da) 2005-01-17
US20030162716A1 (en) 2003-08-28
US8153588B2 (en) 2012-04-10
PT1473040E (pt) 2010-02-02
ES2229511T3 (es) 2005-04-16
CA2294101A1 (en) 1998-12-23
ZA984947B (en) 1999-01-04
DE69826132T2 (de) 2005-09-15
JP2002504140A (ja) 2002-02-05
AU753477B2 (en) 2002-10-17
HK1029738A1 (en) 2001-04-12
WO1998057656A1 (en) 1998-12-23
CA2698626C (en) 2016-02-09
US20140256632A1 (en) 2014-09-11
US6284730B1 (en) 2001-09-04
HK1070816A1 (en) 2005-06-30
US20090118192A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
CY1110287T1 (el) Χρηση της ανθρωπινης παραθυρεοειδους ορμονης
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
EP1064000A4 (en) VITAMIN D AND ITS ANALOGS FOR THE TREATMENT OF TUMORS AND OTHER HYPERPROLIFERATION DISORDERS
ES2055845T3 (es) Composicion farmaceutica para el tratamiento de la osteoporosis.
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ES2190244T3 (es) Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.
MX171191B (es) Composiciones farmaceuticas de glipizida
BR9906796A (pt) Método para a administração de análogos de insulina monoméricos
DE69127470T2 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
GEP20043314B (en) Pharmaceutical Composition Comprising Entacapone, Levodopa, and Carbidopa
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
DK0629400T3 (da) Idebenon-holdige præparater til behandling af Alzheimer's syge
GR3002765T3 (en) New pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient
ATE311897T1 (de) Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
ES2152865A1 (es) Utilizacion de bisfosfonatos en la preparacion de composiciones farmaceuticas para uso intramuscular.
DE60120371D1 (de) Verwendung von wachstumshormon in niederen dosen